MedTrace Logo

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

NCT02365922 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1489

Last updated 2021-05-21

No results posted yet for this study

Summary

Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is to build a FTLD clinical research consortium to support the development of FTLD therapies for new clinical trials. The consortium, referred to as Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL), will be headquartered at UCSF and will partner with six patient advocacy groups to manage the consortium. Participants will be evaluated at 14 clinical sites throughout North America and a genetics core will genotype all individuals for FTLD associated genes.

Conditions

  • FTLD
  • Progressive Supranuclear Palsy (PSP)
  • Frontotemporal Dementia (FTD)
  • Corticobasal Degeneration (CBD)
  • PPA Syndrome
  • Behavioral Variant Frontotemporal Dementia (bvFTD)
  • Semantic Variant Primary Progressive Aphasia (svPPA)
  • Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
  • FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Oligosymptomatic PSP (oPSP)
  • Corticobasal Syndrome (CBS)

Sponsors & Collaborators

  • National Center for Advancing Translational Sciences (NCATS)

    collaborator NIH

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • The Bluefield Project to Cure Frontotemporal Dementia

    collaborator OTHER

  • Tau Consortium

    collaborator OTHER

  • University of California, San Francisco

    lead OTHER

Principal Investigators

  • Adam L Boxer, MD, PhD · Study PI

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2020-08-31
Completion
2020-09-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02365922 on ClinicalTrials.gov